Management of Hilar Cholangiocarcinoma with ERCP

Preoperative Stenting

The American Gastroenterological Association recommends that ERCP with stent placement should be reserved primarily for palliative biliary drainage in unresectable hilar cholangiocarcinoma, while stenting should ideally be avoided prior to assessing resectability to prevent complications that may compromise surgical outcomes 1, 2
Routine preoperative biliary drainage is not recommended for potentially resectable hilar cholangiocarcinoma, except in cases of severely malnourished patients requiring nutritional optimization or acute suppurative cholangitis requiring urgent decompression 1, 2, 3, 4, 5

The European Society of Gastrointestinal Endoscopy recommends using MRCP to plan endoscopic stent placement in complex hilar tumors to reduce the risk of post-procedure cholangitis 1, 2, 3
Unilateral stent placement is sufficient and preferred for most patients with hilar cholangiocarcinoma, with bilateral stenting considered only in selected patients with Bismuth II cholangiocarcinoma where both lobes require drainage 1, 4
The American Society for Gastrointestinal Endoscopy recommends using self-expanding metal stents (SEMS) rather than plastic stents for patients with expected survival >6 months 1, 2, 3

ERCP carries significant procedural risks, including a major complication rate of 4-5.2% and a mortality risk of 0.4% 6, 7, 8, 9, 10
The American College of Radiology recommends that ERCP should be performed with caution in hilar strictures, as suppurative cholangitis may be induced by endoscopic manipulation of obstructed biliary segments 7, 9, 8

If endoscopic stenting fails, consider surgical bypass in patients with good estimated life expectancy (Grade C recommendation) or percutaneous transhepatic biliary drainage (PTBD) as alternative, though associated with higher complication rates and patient discomfort from external drainage 1, 2, 3
The American Gastroenterological Association recommends EUS-guided biliary drainage (hepaticogastrostomy or hepaticoduodenostomy) as alternative to PTBD when ERCP unsuccessful 10

ERCP has limited diagnostic utility in hilar cholangiocarcinoma due to advances in cross-sectional imaging, with an almost exclusively therapeutic role 6, 7, 9, 8, 10, 12
ERCP with EUS may provide imaging and cytologic diagnosis when CT/MRI are negative or equivocal 7, 9, 10